Sept. 29, 2016 — Bruce Haynes, founding partner and president of Purple Strategies, will give the keynote address at the Coalition for Healthcare Communication Member Meeting to be held in Washington, D.C., on Nov. 15-16. Haynes works with some of the world’s best-known brands in the areas of strategy and message development, research, advertising, media […]
Read moreJuly 1, 2016 – Amidst criticism over the high cost of drugs in this country, billionaire and philanthropist Bill Gates said he supports the U.S. drug pricing system, calling it “better than most other systems one can imagine,” according to an article posted yesterday on Bloomberg.com. “The drug companies are turning out miracles, and we […]
Read moreMarch 14, 2016 — The American Medical Association (AMA) as well as Rep. Rosa DeLauro (D-Conn.) and Sen. Al Franken (D-Minn.) are calling for a ban on or restrictions to direct-to-consumer (DTC) drug ads that might result in a dip in drug sales, but also would hurt patients by eliminating the advantages of DTC drug […]
Read moreMarch 10, 2016 — The article below, which covers drug pricing concerns in the news and the success of Merck’s Keytruda in treating President Jimmy Carter, is reprinted with permission by The RPM Report. According to Coalition for Healthcare Communication Executive Director John Kamp, “Drug innovation is expensive but worth it. Thank goodness that Jimmy […]
Read moreFeb. 29, 2016 – When faced with criticism of drug pricing, industry members need to be able to defend drug companies, and arming themselves with the facts is a great start, according to Ilyssa Levins, president and founder of the Center for Communication Compliance, who recently posted an article in Pharmaceutical Compliance Monitor. The article, […]
Read moreDec. 14, 2015 – With medical marketing being targeted by politicians and the media as one cause of high drug prices, the Coalition for Healthcare Communication is helping its members take action against this claim by providing them with a direct-to-consumer (DTC) Tool Kit that includes talking points and other informational resources. “The public and […]
Read moreNov. 9, 2015 – Congress, federal agencies and the media continue to turn up the heat on their examination of drug pricing practices, but the industry is starting to defend itself – with facts. As part of a multi-pronged effort to defend the worth of pharmaceutical companies and their products, the Pharmaceutical Research and Manufacturers […]
Read moreSept. 21, 2015 – Despite widespread reports about the soaring prices of prescription drugs and calls by the federal government and members of Congress to lower these prices and break patents, the Center for Medicine in the Public Interest (CMPI) contends that it is time for a “careful examination of the rest of the story” […]
Read more